The 22,412 Shares of Pfizer Inc. (PFE) are sold by Birmingham Capital Management Co. Inc. AL

The 22,412 Shares of Pfizer Inc. (PFE) are sold by Birmingham Capital Management Co. Inc. AL

Birmingham Capital Management Co. Inc. AL lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 177,253 shares of the biopharmaceutical company’s stock after selling 22,412 shares during the period. Pfizer makes up 2.7% of Birmingham Capital Management Co. Inc. AL’s portfolio, making the stock its 8th largest position. Birmingham Capital Management Co. Inc. AL’s holdings in Pfizer were worth $6,241,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Stelac Advisory Services LLC bought a new position in Pfizer during the second quarter worth about $110,000. Commonwealth Financial Services LLC boosted its position in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the period. Catamount Wealth Management boosted its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. boosted its position in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the period. Finally, Financial Management Professionals Inc. boosted its position in Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 993 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Inc. (NYSE:PFE) traded down 0.97% during mid-day trading on Thursday, hitting $32.75. 10,188,806 shares of the stock were exchanged. The stock has a market capitalization of $198.65 billion, a PE ratio of 29.03 and a beta of 0.86. The company has a 50-day moving average of $34.14 and a 200-day moving average of $34.26. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 EPS. On average, equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.

PFE has been the topic of a number of research analyst reports. Jefferies Group cut their price objective on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 20th. Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target on the stock. in a research report on Tuesday, June 28th. Sanford C. Bernstein set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Pfizer presently has a consensus rating of “Buy” and an average price target of $38.66.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment